Abstract 1880P
Background
Physicians must help patients to maintain motivation and resolve barriers to adherence to treatment, but this does not happen in many cases. The impact of cancer in the coming years will have devastating consequences for the health system since it is the third cause of mortality in the country. Therefore, a substantial change in medical education, health policies is imperative. They are future specialists, the attitudinal barriers could limit their skills and abilities in the task for general surgeons, gynecologists, otolaryngologists, and anesthetists. To detect and change barriers, implement a strategy of 180 minutes in a reflexive focus group.
Methods
Descriptive, non-blind study approved by the Research Ethics Committee (ON23-00003), informed consent was requested from 51 medical residents of the surgical areas of a general hospital who attended a psychoeducational focus group in 2 frequencies, they answered the survey about their beliefs and attitudes regarding the care of cancer patients. 3 key questions were analyzed to ensure knowledge together with reflection, reinforcing empathic attitudes and team collaboration of the participants.
Results
The subjects correctly considered the definition of oncology pre and post-intervention (84 vs 91%), that the treating physician had to give the diagnosis (55 vs 92%) that there is no correct answer for how long a patient would live (89 vs 96%), The term used by the patient to name the cancer doesn´t matter as long as they understand the disease (32 vs 42%), That they should not join the conspiracy of silence proposed by the patient or family (77 vs 91%) If they believed that there is treatment in any stage of cancer (55 vs 87%), if they should care for patients with cancer with a CPR indication vs other chronic patients with hypertensive crisis and DM (64 vs 81%), if they considered palliative care and psycho-oncology for diagnostic phases (63 vs 85%). In the qualitative aspect they left satisfied and mostly looking forward to new sessions that would allow them to carry out their work and education.
Conclusions
There was a percentage impact in generating substantive changes in the opinion of the subjects; this first step should be followed up with more studies and is of relevance to medical educators.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Universidad Autónoma de Nuevo León.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05